NCT03859752: TR1801-ADC in Patients With Tumors That Express c-Met

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: c-Met
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a solid tumor which expresses c-Met
Exclusions: Patients with unstable brain metastases that require treatment- see trial for details

Comments are closed.

Up ↑